Investing in biotech stocks is a high-stakes game with the potential for significant gains and losses. However, the industry’s constant innovation and the expected cutback in interest rates make it an attractive area for investors willing to take on risk. IntraCellular Therapies (ITCI), Viking Therapeutics (VKTX), and Novo Nordisk (NVO) stand out as three companies with promising pipelines and solid financial footing.